TouchPoint Solutions, Inc. – CEO
Dendrite International – Group President
GlaxoSmithKline – Group Director, Corporate Business Strategy and Planning
Isuta Holdings – CEO
Baxter/Merck KGaA – Director, International Business
Ben Franklin Technology Partners of Pennsylvania – Life Science Investment Advisory Committee
Celerant Consulting – Executive Board
Hepatitis B Foundation
NuPathe Inc. (NASDAQ:PATH)
Sotera Wireless, Inc.
University City Science Center (Philadelphia) - Vice Chairman
B.B.A. – Marshall University
M.B.A. – University of New Haven
Advanced Management Program – The Wharton School at The University of Pennsylvania
James A. Datin
Executive Vice President and Managing Director
With a multinational track record of success, Jim applies his expertise to drive Safeguard’s partnership opportunities in both healthcare and technology.
Over the course of his 25+ year career, Jim has been a successful CEO, raised capital for entrepreneurs to grow companies, and has turned around troubled companies throughout the United States, Europe and Asia. In addition, he has completed more than 50 transactions including venture investments, buyouts, acquisitions, mergers, IPOs, licensing and partnership agreements.
At Safeguard Scientifics, Jim applies his expertise to drive Safeguard’s partnership opportunities in both healthcare and technology, specifically MedTech, including diagnostics and devices, HealthTech, including Heathcare IT, specialty pharmaceuticals, Digital Media, FinTech (Financial Technology) and Enterprise 3.0, which includes mobile technology, cloud, the Internet of Things and big data.
Prior to Safeguard, Jim was CEO of Touchpoint Solutions; Group President of Dendrite International; Group Director, Corporate Business Strategy and Planning at GlaxoSmithKline; CEO of Isuta Holdings Berhad; and Director, International Business at Baxter/Merck KGaA.
Jim is a former board member of Intralinks, where he chaired the audit committee and filed the company’s SEC Form S-1 for its initial public offering. The company was acquired by TA & Associates, a large private holding firm, for more than $430 million, representing a 6x return to investors.
Jim is currently a member of the board for Safeguard’s partner companies NovaSom, NuPathe (NASDAQ:PATH), Putney and Sotera Wireless. In addition, Jim is on the board of Pennsylvania, BIO; the Executive Board for Celerant Consulting; the Life Science Investment Advisory Committee for Ben Franklin Technology Partners of Pennsylvania; the board for Hepatitis B Foundation; and is Vice Chairman of the board for the University City Science Center in Philadelphia. He is a NASDAQ accredited and certified board member.
Jim graduated on the Dean’s List with a B.B.A. degree from Marshall University where he also earned awards in intercollegiate athletics. He earned an Executive M.B.A. with Honors from the University of New Haven and has completed executive management programs at UCLA, the University of Chicago, and The Wharton School at the University of Pennsylvania.